Abstract. Several studies have reported that antibody to hepatitis B core antigen (anti-HBc) positivity may influence the development of hepatocellular carcinoma (HCC) in chronic hepatitis C patients, but the evidence is still not conclusive. In this study, we examined whether the presence of antiHBc positive was associated with the development of HCC in hepatitis C virus (HCV)-infected subjects among the residents in an HCV hyperepidemic area who were followed up for 12 years. In an HCV hyperendemic area (positive rate of anti-HCV: 23.4%), 509 residents were examined by health screening in 1990. After 12 years of follow-up, we evaluated the risk factors for HCC. The incidence of HCC was compared between anti-HBc positive and anti-HBc negative subjects after 12 years of prospective observation. Univariate and multivariate analyses were conducted to determine risk factors for the development of HCC. The incidence of HCC was significantly higher in the anti-HBc positive group (13 subjects) than in the anti-HBc negative group (0 subjects) (P=0.012). Multivariate analysis identified positivity for antiHBc and HCV RNA, history of icterus, and female gender as independent determinants of the development of HCC. Our findings provide clear evidence in a prospective study that presence of anti-HBc, that is, past hepatitis B virus (HBV) infection, is a risk factor for the development of HCC in HCVinfected people.
Introduction
The number of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection carriers worldwide is estimated at 350 million (1) and 170 million (2), respectively. HBV and HCV infections include substantial proportions of cases with past infection, asymptomatic carriers, acute hepatitis and chronic hepatitis, and HBV infections may cause fulminant hepatitis. Especially, chronic HBV and HCV infections may lead to cirrhosis and hepatocellular carcinoma (HCC) (1, 3) . It was reported that the frequency of HCC due to chronic HCV infection is higher in Japan than in any other country (4) . Several studies have reported that occult HBV infection may also be one of the causative factors of HCC (5, 6) . The presence of occult HBV infection is diagnosed based on the fact that HBV DNA still exists in serum and liver tissue after hepatitis B surface antigen (HBsAg) disappears in acute or chronic HBV infection (7) (8) (9) , or even after antiviral treatment is successful. Although some studies reported that occult HBV infection is associated with HCV-related liver dysfunction (10) or the development of HCC (11) (12) (13) , these associations have still not been clearly demonstrated in a prospective study.
A higher incidence of HBV DNA is commonly seen in patients with anti-HBc-positive serology than in those with anti-HBc negative serology in coinfections with HBV and HCV (10) , and using PCR amplification, most studies have demonstrated the presence of the HBV DNA genome in 22% to 87% of the patients who are HBsAg negative and HCV RNA positive (10, (14) (15) (16) (17) (18) . Some studies showed that HBV infection could occur in recipients of livers donated from subjects with anti-HBc but without HBsAg (19, 20) . That is, anti-HBc, which was initially considered to be an index for the past HBV infection in which all HBV had been cleared, has emerged as a convincing marker of occult hepatitis B (19, (21) (22) (23) . Also, several studies showed that the anti-HBc positivity was associated with the development of HCC in patients with HCV-associated chronic liver disease (11, (24) (25) (26) , but these associations have not been clearly demonstrated.
Since 1990, we have conducted health screenings of the residents of H town (adult population: 7,389), Fukuoka prefecture in northern Kyushu, Japan (27) . This town is known for its high prevalence of liver disease. We previously reported that the town had a high prevalence of HCV carriers, 120/509 (23.6%) in 1990, and that HCV infection was the principal cause of liver dysfunction and HCC (27, 28) .
In the present study, we analyzed the influence of anti-HBc positivity on the development of HCC in HCV-infected people in the same town during 12 years in a prospective manner.
Subjects and methods
Subjects. In 1990, of a total 9,799 inhabitants, 739 (10%) of the 7,389 inhabitants >20 years old were randomly selected as follows: the names of the residents (as they appeared on their resident cards) were arranged in order according to the Japanese phonetic syllabary. Then every tenth resident was selected. As a result, 509 subjects (6.9% of H town residents) gave their informed consent to participate in the study.
Of 509 participants initially screened in 1990, 69 people had died and 55 people had moved to other regions as of 2002. Thus, 385 of the original 509 residents survived in the area and 139 residents agreed to participate in the medical follow-up survey, while 26 did not agree to participate, and the remaining 220 residents did not declare their intention either way in 2002. For 14 of these remaining 220 inhabitants, the records were obtained from the primary physicians. Consequently, we analyzed the outcome in terms of the liver disease in 222 inhabitants (69+139+14) in 2002.
Information on cigarette smoking, alcohol consumption, and history of icterus, and blood transfusion was obtained at the time of enrollment through interviews by the doctors in charge and experienced public health nurses. Smoking was defined as >10 cigarettes per day for >10 years. Alcohol consumption was defined as a daily intake of ≥75 g of ethanol per day for >10 years.
Serological assay. In 1990, sera were collected from all the participants, and conventional liver function tests were performed: serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gammaglutamyl transpeptidase (Á-GTP), total protein (TP), albumin (Alb), total cholesterol (TC), total bilirubin (TB), zinc turbidity (ZTT) were measured. Anti-HCV was measured using HCV PHA 2nd generation kits (Dainabot Co. Ltd., Tokyo, Japan). These results were confirmed using a second generation recombinant immunoblot assay (RIBA II) (Ortho Diagnostic System, Tokyo, Japan). Measurement of HBsAg and anti-HBc was performed with an enzyme immunoassay kit (Mizuho Medy Co. Ltd., Tosu, Saga, Japan). Titers of anti-HBc yielding >70% inhibition were assessed as positive.
Detection of HCV RNA by RT-PCR.
All subjects who were anti-HCV-positive were tested for the presence of serum HCV RNA, which was detected by reverse transcription-nested polymerase chain reaction (RT-nested PCR) using primers based on the sequences of the 5'UTR (untranslated region) of the HCV genome, as described previously (29) .
Statistical analysis. Continuous data were expressed as mean ± SD, minimum and maximum. Categorical data were expressed as frequency and/or percentage. For comparing the background between anti-HBc positive and negative, the ¯2 and Wilcoxon's test were used to analyze quantitative data. Univariate and multivariate analysis were performed by logistic regression to calculate odds ratio and its 95% confidence interval. The SAS (statistical analysis system) computer program (release 8.2; SAS Institute Inc., Cary, NC, USA) was used for the logistic regression. A P-value of <0.05 was considered statistically significant.
Results
In 2002, anti-HCV was detected in 74 of the 222 inhabitants (Fig. 1) . HCV RNA was detected in 53 (71.6%), HBsAg in 1 (1.4%), and anti-HBc in 53 (71.6%) of these 74 people. We asked the primary physician of these 74 inhabitants about the diagnosis of liver disease, and found thereby that 8 inhabitants had died of HCC and 5 inhabitants had been treated for HCC (total 13 inhabitants).
The 74 inhabitants were divided into two groups: 53 who were positive and 21 who were negative for anti-HBc, and the clinical characteristics observed in the screening were compared between the two groups. No significant differences were observed between the two groups in age, sex, smoking, history of icterus or blood transfusion, alcohol consumption, ALT level, HBsAg, or HCV RNA. Significant differences were observed for the incidence of HCC (13 versus 0) between these two groups (P=0.012) ( Table I) .
Univariate and multivariate analyses of factors that influenced the incidence of HCC. The influence of age, sex, smoking, history of icterus, history of blood transfusion, alcohol consumption, AST, ALT, Á-GTP, TP, Alb, TC, TB, ZTT, anti-HBc and HCV RNA on the development of HCC was analyzed by univariate and multivariate analyses. Table II shows the basic characteristics of the 74 inhabitants with anti-HCV divided into two groups: a group with HCC (HCC group) and a non-HCC group, and shows the results of univariate analyses. The mean age and sex were not significantly different between the HCC group and non-HCC group. Serum levels of AST, ALT, Á-GTP, TB, and ZTT were significantly higher in the HCC group than in the non-HCC group (P<0.05). The serum level of Alb was significantly lower in the HCC group than in the non-HCC group (P<0.05). The frequency of anti-HBc, HCV RNA, and history of icterus were significantly higher in the HCC group than in the non-HCC group (P<0.05). The frequency of smoking, alcohol Table I . Characteristics of anti-HCV positive patients with and without anti-HBc. 
-----------------------------------------------------------------------------------------------------
Age and serum ALT level were expressed as mean ± SD. HCC, hepatocellular carcinoma; NS, not significant. Table II . Univariate analysis of risk factors that influence the development of HCC. 
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consumption, and history of blood transfusion were not significantly different between the HCC group and non-HCC group. Multivariate logistic regression analyses identified anti-HBc positivity, HCV RNA positivity, history of icterus, and female sex as independent risk factors for the development of HCC (Table III) .
Discussion
Several studies have shown that anti-HBc positivity was associated with the development of HCC in patients with HCV-associated chronic liver disease (11, (24) (25) (26) . However, considering the natural history of all HCV infections, the results of those previous studies have some problems, i.e., the observation period was short and the research was performed in a retrospective manner in patients with chronic hepatitis and liver cirrhosis. Our study was a prospective study that investigated the disease progress after 12 years, and was thought to reflect the natural history of HCV infections, because we did not investigate only HCV-associated chronic liver disease but also covered all HCV infections such as past HCV infection and asymptomatic carriers of HCV (30, 31) . In this study, we obtained clear evidence that anti-HBc-positivity was a risk factor for the development of HCC in HCV-infected people.
It has been suggested that HBV can induce liver tumor formation by at least two distinct mechanisms. First, HBV DNA sequences are frequently found integrated into chromosomes of hepatocytes that have evolved into HCC, and a direct role of HBV in hepatocarcinogenesis has thus been inferred (32, 33) . Second, HBV DNA sequences may be caused by disruption of tumor suppressor gene function (34) . It has been shown that HBV DNA sequences can be detected in some of the liver or serum from anti-HBc-positive patients (9, 10) , and the presence of anti-HBc does not entirely exclude the possibility of chronic HBV infection. Though the presence of anti-HBc has been used as a marker of past HBV infection, the integration of HBV DNA in hepatocytes may cause carcinogenesis, as noted above. That is, anti-HBcpositivity may represent occult HBV infection. The presence of anti-HBc alone, in the absence of HBV DNA testing, has been used in some studies as a marker of occult hepatitis B (19, (21) (22) (23) . Pollicino et al provided clear evidence that occult HBV was a risk factor for the development of HCC and showed that the potential mechanisms whereby HBV might induce tumor formation occur in most cases of occult infection (6) .
To detect occult HBV infection, it is necessary to examine whether HBV DNA is present. However, serum HBV DNA levels are frequently below the limits of detection in anti-HBcpositive patients, and there is a pronounced risk of falsepositive results from contamination (35) or amplification of non-HBV-DNA targets, and the sensitivity of detection is variable (36, 37) . In a previous study in which serum HBV DNA was tested in 20 anti-HBc positive patients with HCVassociated HCC, HBV DNA was not detected by a real-time PCR assay with a minimum detection limit of 10 1.7 copies/ml (1.7 log copies/ml) (38, 39) . Considering these results, it might not be possible to detect serum HBV DNA in some anti-HBc-positive subjects. Therefore, if we could examine liver tissues by PCR to examine whether occult HBV infection is present, we could be more certain of the presence of occult HBV infection.
In contrast to our findings, in some studies anti-HBc positivity was not found to be associated with the development Table III . Multivariate analysis of risk factors that influence the development of HCC. 
.05; HCC, hepatocellular carcinoma; CI, confidence interval.
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of HCC in patients with HCV-associated chronic liver disease (9, 39, 40) . One study showed that anti-HBc was detected significantly more frequently in blood donors with than without anti-HCV, but the prevalence of anti-HBc was no different between the patients with HCV-associated HCC and anti-HCV-positive blood donors. Therefore, no epidemiological evidence was obtained for a role of past HBV infection in hepatocarcinogenesis in patients infected with HCV in Japan (40) . Also, Yano et al showed that the clinical features of HCV-associated HCC were unaffected by anti-HBc-positivity (39) . In addition, a study in Taiwan suggested that occult HBV infection might have little influence on the clinicopathologic course of chronic HCV infection (9) . It was reported that the frequency of HCC due to chronic HCV infection is higher in Japan compared with any other country (4) . If the frequency of HCC due to chronic HCV infection is high, it is necessary to consider the possibility that anti-HBc positivity may be associated with hepatocarcinogenesis. In addition to HBV, other environmental and host factors might also be associated with the pathogenesis of HCC (4, (41) (42) (43) .
We continued carrying out health screenings of the residents of H town and conducted a cohort study of liver disease among the same residents over a 12-year period. The results of this study showed that anti-HBc is associated with the development of HCC in HCV-infected people.
